Bisphosphonates: beyond prevention of bone metastases.
Gad
G
Rennert
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology*; D014408:Biomarkers, Tumor / Q000032:analysis*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000453:epidemiology* / Q000517:prevention & control*; D004164:Diphosphonates / Q000627:therapeutic use*; D011307:Drug Prescriptions / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology* / Q000517:prevention & control*; D009369:Neoplasms / Q000453:epidemiology* / Q000517:prevention & control*; D011960:Receptors, Estrogen / Q000032:analysis*; D055502:Secondary Prevention; D019821:Simvastatin / Q000008:administration & dosage*; D014728:Veterans / Q000706:statistics & numerical data*
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011960:Receptors, Estrogen; D019821:Simvastatin